Delivering Pharmaceutical Innovations Domestically and Globally

Toward Realizing the JPMA's Vision for 2035We are moving forward with our activities centered on the three pillars of Innovation, Access, and Trust.

Toward Realizing the JPMA's Vision for 2035

Update Information

Social Media News

November 5, 2026

# We have published Issue No. 79 (November 2026) of the “ OPIR Views and Actions” 📰

Case Study on the Development of a Drug Discovery Ecosystem: Seoul, South Korea
—Bio and Drug Discovery Policies as a National Strategy—

In addition, we present surveys, analyses, and research on the pharmaceutical industry, as well as updates on the Policy Research Institute’s activities.📊

https://www.jpma.or.jp/opir/news/index.html
#PolicyResearchInstitute #DrugDiscovery #ClinicalTrials #Approval

November 4, 2026

#JPMA #Newsletter The November 2026 issue (No. 231) has been published! ✨

✅TOWN HALL MEETING
✅Feature: “Business Strategy Division”
✅From JPMA: “Interview with Executive Director Takahashi”
✅My Committee: “Vol. 8: Drug Evaluation Committee”
✅The Pharmaceutical Industry Through the Lens of Facts
✅Key Terms to Keep in Mind
✅Topics

https://www.jpma.or.jp/news_room/newsletter/231/index.html

October 28, 2026

Yasunori Yoshida, Executive Director of the JPMA, spoke at “CHUGAI PHARMONY DAY 2026,” hosted by CHUGAI PHARMACEUTICAL CO., LTD.

Under the theme “How should we collaborate to turn efforts to solve patients’ challenges into a major movement?”, he exchanged views with representatives from patient organizations and companies.

#CHUGAIPHARMONYDAY2026 #CHUGAI #ChugaiPharmaceuticals

October 28, 2026

The 13th Nikkei Infectious Diseases Conference
The JPMA hosted a sponsored session titled “Putting the MCM Strategy into Action—Implementing Infectious Disease Response Capabilities in Society.”
Vice Chairman Isao Teshirogi took the stage, and a discussion was held among representatives from industry, government, and academia.

Preparing for an infectious disease crisis is too late once the crisis has already occurred.
It is essential to engage in ongoing discussions during peacetime, widely communicate the importance of preparedness to society, and build a system where society as a whole prepares, while gaining understanding and support.

October 28, 2026

Exchange of Views Held with a Delegation of Members of the European Parliament Visiting Japan

Six members of the European Parliament’s Committee on Public Health visited the #JPMA during their trip to Japan.

They engaged in a lively exchange of views with members of the JPMA’s Biopharmaceutical Committee, Drug Evaluation Committee, Intellectual Property Committee, and International Affairs Committee regarding challenges facing the pharmaceutical industries in Europe and Japan.

October 21, 2026

October 21 is #GlobalEthicsDay
The#JPMA is participating in “Re-centering Ethics” alongside #IFPMA .

As AI and digital innovation advance rapidly, we are placing ethics and integrity at the center of all decision-making.

We aim for trusted innovation alongside the global pharmaceutical industry.

For more details on “Re-centering Ethics,” please visit the following page 👇
https://pharmaboardroom.com/articles/re-centering-ethics-as-pharmas-competitive-advantage/

October 15, 2026

#JPMA #International Affairs Committee #NorthAmericaGroup We hosted Mr. Tani from JETRO NY for a discussion on U.S. healthcare policy.

We engaged in a wide-ranging exchange of views on the latest policy and market trends surrounding U.S. healthcare—including the political landscape, tariff policies, pharmaceutical pricing policies (including MFN), and PBM regulations—as well as their implications for Japan.

October 15, 2026

The JPMA’s #Code Compliance Committee will once again hold the “Code of Practice: #JPMA Code Awareness Month” in November of this fiscal year 📢

[This Year’s Theme]
From Understanding to Action ~Each of Our Actions Builds Trust~

⬇Click here for details!
https://www.jpma.or.jp/news_room/release/2026/261015_code.html

October 9, 2026

Toward a Japan Free of #DrugLoss
Mr. Sakakibara, Head of the Business Strategy Division at the JPMA , served as moderator at a luncheon seminar held during #BioJapan2026.
They discussed the drug discovery ecosystem necessary to deliver innovative medicines to patients as quickly as possible.

October 9, 2026

#BioJapan2026 It’s finally the last day!

At the JPMA Booth C-74, we are currently holding a “Journey Through the Drug Discovery Ecosystem” stamp rally in collaboration with #AMED, #LINKJ, and medU-net .

The stamp rally ends today.
Please be sure to stop by Booth C-74!

#JPMA Co-hosted Luncheon Seminar
“A Japanese Ecosystem That Eliminates Drug Loss Through Industry-Government-Academia Collaboration”

The event will be held in Room F202 starting at 11:30 AM!

October 8, 2026

🎉Professor Kenzo Kogai Wins the #NobelPrizeinChemistry 🎉

We extend our heartfelt congratulations to Professor Kogai as his many years of research and dedication have borne fruit, and his achievements have been recognized with the world’s highest honor.

October 8, 2026

#BioJapan2026 On the second day as well, at the JPMA booth C-74 ,
#R & D Committee
#Biopharmaceutical Committee
# The Office of Pharmaceutical Industry Research
will be presenting poster exhibits.
Our highly popular stamp rally is also underway—we hope you’ll join us!

⬇️Click here for the stamp rally
https://petanco.net/peta/zsykbnTdFgZIhe9DWmHf

October 7, 2026

#Miyabashira’s Musings💬
Delivered a keynote speech at #BioJapan2026 , which celebrated its 40th anniversary.
Key themes included the #JPMA’s co-creation initiatives in the biotech and drug discovery fields and the importance of human capital.
It was a day where I could sense the future potential of Japan’s biotech industry through the presentations by domestic and international speakers and the energy in the venue.

October 7, 2026

#BioJapan2026 kicks off today!

Chairman Miyashira will deliver the keynote address titled “Shaping the Future of Japan’s Biopharmaceuticals Through Co-creation.”

In addition to the presentation, please be sure to stop by the JPMA booth (C-74).
This year, we’re also holding a stamp rally in collaboration with #AMED, #LINKJ , and medU-net !

Please join us! 👇
https://petanco.net/peta/zsykbnTdFgZIhe9DWmHf

October 7, 2026

Joint Statement by Three Pharmaceutical Associations from Japan, the U.S., and Europe

We are deeply concerned that a proposal to expand drug price reductions under the cost-effectiveness evaluation system has been presented and that the Central Social Insurance Medical Council has endorsed this direction.

#JPMA, #PhRMA, and #EFPIA strongly urge the Japanese government to reconsider this proposal and engage in thorough discussion.

Click here for details on the joint statement
https://www.jpma.or.jp/news_room/release/2026/261007.html

October 2, 2026

\Featured in The Japan Times📰/

A joint op-ed by Go Takahashi, Executive Director of the #JPMA, and David Reddy of #IFPMA was published in the opinion section of #JapanTimes !

They discuss the importance of adult vaccinations in an aging society.

Be sure to check it out 👇
https://www.japantimes.co.jp/commentary/2026/09/29/japan/japan-leads-preventive-health-pay/

October 1, 2026

Today, #JPMA took a new step forward as the “Japan Pharmaceutical Manufacturers Association” ✨

We are committed to strengthening Japan’s drug discovery capabilities and contributing to the advancement of global healthcare.

“Turning change and challenges into strength. Expanding the circle of co-creation.”

Please see the press release below 👇
https://www.jpma.or.jp/news_room/release/2026/261001.html

September 28, 2026

On September 25, in New York, #JPMA Vice Chairman Manabe met with Richard Hatchett, CEO of CEPI.
 
They exchanged views on pandemic preparedness, innovation, and public-private partnerships, and shared the importance of building a sustainable ecosystem.
 
#UNGA81 #GlobalHealth #CEPI

September 28, 2026

\Hosting a Side Event at the #UN GeneralAssembly/
 
The JPMA hosted an event in New York under the theme “Building Resilient and Sustainable Health Systems” ✨
 
Representatives from the World Bank, international organizations, and various countries participated, sharing insights on health and fiscal coordination, the utilization of medical innovation, and the importance of peer learning.
 
#UNGA #UHC #GlobalHealth #International Affairs Committee

August 24, 2026

We have launched a call for proposals for our #ResearchGrantProgram 📢

The JPMA provides grants aimed at contributing to solving challenges in healthcare, health, and the pharmaceutical industry through interdisciplinary research and support for early-career researchers.
🗓️ The application deadline is Monday, November 16.

Click here for detailed program information 👇
https://www.jpma.or.jp/information/industrial_policy/researchsupport/index.html

August 3, 2026

#Japan Pharmaceutical Manufacturers Association (JPMA) #Newsletter The July 2026 issue (No. 230) has been published! ✨

✅Featured Interview: “Business Strategy Division”
✅From JPMA: “Interview with the New Chairperson”
✅My Committee: “Regulatory Affairs Committee”
✅The Pharmaceutical Industry Through the Lens of Facts
✅Key Term to Watch: “Public-Private Investment Roadmap”
✅Topics

Be sure to check it out 👇
https://www.jpma.or.jp/news_room/newsletter/230/index.html

August 3, 2026

The #Quality & Technology Committee will once again host the “GMP Case Study Seminar” on Friday, September 25, 2026!

Under the theme “Integrating On-Site Capabilities, Equipment Reliability, and Digital Technology to Enhance the Effectiveness of Quality Assurance,” the event will feature a special lecture by the PMDA and three presentations from companies and industry representatives. We look forward to your participation!

Register here 👇
https://www.jpma.or.jp/news_room/event/information/GMP2026.html

July 29, 2026

We extend our heartfelt sympathies to all those affected by the recent earthquakes centered in Kumamoto Prefecture.
We also express our deepest respect to all those working tirelessly on rescue, recovery, medical, and relief efforts amid the ongoing aftershocks.
 
While we have received reports that medical institutions have also been affected, the JPMA will work closely with the government, relevant agencies, and our member companies to assess the situation and ensure we are prepared to swiftly provide necessary medications.
 

July 21, 2026

🆕#JPMA News Release
Following the Cabinet’s approval of the “#Basic Policy 2026,” the #JPMA has Chairman #Miyashira .

We welcome the fact that drug discovery and advanced medical care have been positioned as key sectors supporting Japan’s growth, and that a direction has been set to appropriately evaluate the value of innovative new drugs.

Click here for the statement: https://www.jpma.or.jp/news_room/release/2026/260721.html

July 14, 2026

#Miyashira’s Musings💬
On July 10, I participated in the #Public-Private Council for Enhancing Drug Discovery Capabilities.
Medicines are not a “cost”—they are an investment in the future that protects the lives and health of the public.
The world is currently watching Japan’s pharmaceutical policies closely.
 
We will work together—public and private sectors united—to realize the future outlined in the Public-Private Investment Roadmap of Japan’s Growth Strategy!
#JPMA #PrimeMinisterTakaichi
 

July 10, 2026

At the #NIKKEI Drug Discovery Ecosystem Summit Day 2, we held a JPMA special session titled “The New Drug Discovery Ecosystem Nurtured Through Co-creation”!
Panelists from the government, public administration, universities, and pharmaceutical companies gathered to engage in a passionate discussion on strengthening Japan’s drug discovery capabilities, focusing on key themes such as innovation, commercialization, talent mobility and development, and economic rationality!
 

July 9, 2026

Yesterday, Vice Chairman Okuda of the #JPMA took the stage at the organizer panel session titled “Global Collaboration” during Day 1 of the #NIKKEI Drug Discovery Ecosystem Summit!

He emphasized the importance of building a drug discovery ecosystem where drug discovery seeds and intellectual property (IP) are generated based on strong basic research capabilities, and where capital and talent accumulate and circulate. 🌱

Click here for the day’s program 👇
https://events.nikkei.co.jp/81973/

July 7, 2026

#International Affairs Committee: Europe and U.S. Subcommittee and Field Trip Subcommittee @Tokushima

As part of the annual field trip subcommittee—which includes visits to facilities owned by member companies—we visited the Otsuka Pharmaceutical plant in Naruto City, Tokushima Prefecture this year.

Participants learned about the history, technology, and evolution of intravenous solutions while touring the birthplace of the Otsuka Group. They also engaged in lively discussions with one another.

#JPMA

July 6, 2026

July 6 is Vaccine Day. On this day in 1885, Pasteur administered the first human vaccination against rabies. Vaccines can prevent disease. From children to adults, accurate knowledge leads to peace of mind. You can learn about the history of Pasteur’s pioneering work at the Pharmaceutical Research Institute 👇

https://www.jpma.or.jp/junior/kusurilabo/history/person/pasteur.html

#VaccinePracticeCommittee #VaccineDay

July 2, 2026

# OPIR Views and Actions No. 78 (July 2026) has been published 📰

✅ Status of Drug Development for Unmet Medical Needs

In addition, we feature surveys, analyses, and research on the pharmaceutical industry, as well as updates on the Policy Research Institute’s activities 📊

⬇ Click here for details
https://www.jpma.or.jp/opir/news/index.html

#PolicyResearchInstitute #PharmaceuticalMarket #AI

May 29, 2026

In addition to Prime Minister Takaichi, Chairman Miyashira, President Kinoshita, and Executive Director Takahashi from the #JPMA also participated in meetings with Finance Minister Katayama, Health, Labor, and Welfare Minister Ueno, and LDP Policy Research Council Chairman Kobayashi!

May 29, 2026

The Biopharmaceutical CEOs Roundtable ( #BCR ) was held in Tokyo!
The #JPMA, together with leaders of global biopharmaceutical companies, participated in an exchange of views with #PrimeMinister Sanae Takaichi 🤝
Lively discussions took place regarding the promotion of innovation through drug discovery and advanced medical care, as well as strengthening Japan’s competitiveness in the life sciences.
(Photo courtesy of the Prime Minister’s Office 📸)

May 28, 2026

🆕#JPMA News Release

A delegation of more than 20 leaders from major biopharmaceutical companies in the U.S., Japan, and Europe met with Prime Minister Sanae Takaichi this week to discuss the initiatives necessary for Japan to maintain and strengthen its leadership in the life sciences sector.

Click here for details 👇
https://www.jpma.or.jp/news_room/release/2026/260528.html

May 22, 2026

Co-hosted a side event with the Permanent Mission of Japan to the International Organizations in Geneva at the 79th World Health Assembly (WHA79).

Approximately 45 participants, including ministers from Ghana, Fiji, Jamaica, and Vietnam, as well as representatives from international organizations and NGOs, attended the event to share insights on Japan’s “Kenshin” (health checkups) and examples from their respective countries. A lively discussion took place on strengthening sustainable health systems through prevention and early detection.

#International Affairs Committee

May 1, 2026

🎉Today, May 1
The JPMA, which has marked many milestones since its founding in 1968, celebrated its anniversary!
We would like to express our heartfelt gratitude to the many people who have supported us throughout our journey.

And with this day marking a new milestone—
We will continue to make steady preparations for our full-scale launch as a general incorporated association, scheduled for October ✨

April 30, 2026

#Miyashira’sMusings💬
The #JapanGrowthStrategyCouncil, which has held discussions for about four months.
Following the Drug Discovery and Advanced Medical Care Working Group, I also participated in the final session of the Synthetic Biology and Biotechnology Working Group!

I would like to express my heartfelt gratitude to all the members and to the officials from the relevant ministries and agencies who worked so hard to bring this together.

Drawing strength from the roadmap we’ve mapped out together, all that’s left is to move forward!
#JPMA

April 28, 2026

#Miyashira’s Musings💬
I participated in the final meeting of the #Japan Growth Strategy Council’s “Drug Discovery and Advanced Medical Care Working Group,” following nearly four months of discussions!

The pharmaceutical industry is a vital strategic sector that supports life, health, economic growth, and national security.

Bringing innovative Japanese pharmaceuticals to the world —
Let’s move forward as one—government and industry united!
#JPMA

April 23, 2026

#Miyashira’s Musings💬

Speaking at #CPHI2026!
The true measure of success in healthcare digital transformation is “what benefits have reached each and every citizen.”
Quality of care, work styles, management, and patient outcomes.
Quantitatively demonstrating value accelerates the next phase of implementation.
I am grateful for the opportunity to discuss the potential of the future healthcare ecosystem.

April 22, 2026

The “15th Asia Pharmaceutical Association Conference ( #APAC )” was held on April 21.

This year, we once again welcomed not only representatives from pharmaceutical associations but also regulatory authorities and academics from various Asian countries and regions, including Japan. With approximately 700 participants, we held meaningful discussions. ✨

Click here for this year’s agreed items 👇
https://www.jpma.or.jp/news_room/release/2026/260422_02.html

#JPMA

April 20, 2026

#JPMA #International Affairs Committee regularly exchanges information with overseas pharmaceutical associations, and this time held an online meeting with #EFPIA.

During the meeting, both JPMA and EFPIA shared updates on policy and regulatory trends affecting the pharmaceutical industry and exchanged views on common challenges such as most-favored-nation treatment and tariffs.

April 14, 2026

The North America Group of the Europe and America Subcommittee under the #JPMA #International Affairs Committee hosted a study session featuring Mr. Lu (Greenberg Traurig), a lawyer practicing in the United States, as a guest speaker.

He spoke about policy and regulatory trends surrounding the U.S. pharmaceutical industry, and participants exchanged views.

April 9, 2026

🆕News Release

The Council for the Proper Use of Medicines, the Japan Pharmacists Association, and the JPMA collaborated to produce “Don’t Take Information at Face Value!”—an educational resource for the general public that summarizes tips for evaluating medical and health information—which was published on each organization’s website on April 9.

Click here for details 👇
https://www.jpma.or.jp/news_room/release/2026/260409.html

April 8, 2026

“Drug Discovery Karuta,” created by middle and high school girls, is now available! ✨

Download here 👇
https://www.jpma.or.jp/information/industrial_policy/report/260402.html

They expressed the realities of drug discovery—including AI, iPS cells, drug-resistant bacteria, and drug loss—in their own words!
#GirlsMeetSTEM #STEM #ScienceandTechnologyMuseum #AlchemyNote

April 8, 2026

On April 3, we held an exchange meeting between the#JPMA #Quality & Technology Committee’s Quality Culture Project and the Toyama Pharmaceutical Association. This marks the third such meeting, following those held in 2025.

On the day of the event, lively discussions took place regarding quality culture. The content of this exchange will be shared with the JPMA GMP Case Study Group in the future and utilized to further our quality assurance efforts!

April 3, 2026

On March 28, #JPMA Chairman Miyashira took the stage at the Pharmaceutical Society of Japan’s Diversity Promotion Symposium! He spoke about talent development initiatives in the pharmaceutical industry and the importance of diversity in driving innovation!

April 2, 2026

#JPMA held a career awareness seminar for middle and high school students at the Japanese Pharmaceutical Society’s Annual Meeting last weekend ✨

How are medicines created and delivered to patients? 💊 Through this story, we introduced the appeal and fulfillment of careers in pharmacy and drug discovery!

We hope this serves as an opportunity for the young people who will lead the next generation of pharmacy and drug discovery to envision their own futures🌱

April 2, 2026

#JPMA also sponsored the “63rd Senden Kaigi Awards: Junior High and High School Division.”
From among the many entries, more than 100 JPMA members participated in the judging process and selected six winning taglines🏅

Congratulations to all the winners!🎉
The selected entries will be used in the JPMA’s future public relations activities!

Click here for details on the judging process and interviews with the winners 👇
https://www.jpma.or.jp/information/public_affairs/pr/2025/index.html

April 1, 2026

🌐 The JPMA website homepage has been redesigned

Based on the three pillars of JPMA’s Vision for 2035 (Innovation, Access, and Trust), we’ve reorganized the site to better organize and visualize JPMA’s activities. 👇

https://www.jpma.or.jp/

Following the recent introduction of “automatic translation (English),” we will continue to strive to strengthen our ability to communicate both domestically and internationally ✨

View the X post

About JPMA

Under the JPMA Board of Directors, 12 committees composed of member companies and 6 specialized organizations, including the Office of Pharmaceutical Industry Research (OPIR) which functions as a think tank, carry out a wide range of initiatives. These activities aim to establish a robust drug discovery ecosystem for the development of innovative pharmaceuticals, ensure compliance with regulatory frameworks such as the Pharmaceuticals and Medical Devices Act, and build trust with key stakeholders.

Each committee and specialized body bring together a diverse pool of talent - from young professionals to experienced experts - working across organizational boundaries. Through mutual collaboration and constructive exchange, they advance pharmaceutical innovation, promote the appropriate use of medicines, enhance transparency in distribution, foster international cooperation, and formulate policy proposals. In addition, JPMA conducts various surveys and research projects to address industry-wide challenges. By working closely with government authorities, patient advocacy groups, and other relevant organizations, JPMA supports the sound and sustainable development of the pharmaceutical industry.

Click here for details

JPMA's Vision

01
Innovation

Consistently produce innovations to benefit health spans and the economy

  • Pharmaceutical innovations
  • Leading-edge scientific technology
  • Pharmaceutical manufacturing technology
  • Domestic manufacturing infrastructure
  • Making Japan a science and technology powerhouse
  • Fostering highly skilled talent
  • PPI/E
  • Drug discovery that involves patients and the public
  • Co-creation
  • Drug discovery ecosystem
  • Job creation
  • Extending health spans
  • Well being
  • Pharma as a core industry
  • Economic growth
02
Access

Bring innovative new drugs to the public more quickly to enhance health security

  • A social security system that gives patients swift access to “the latest treatments” and stable access to “global-standard treatments”
  • Positive investment cycle
  • Building an attractive domestic market
  • Drug pricing that properly factors in the worth of innovation
  • Health security for Japan
03
Trust

Commit to ethical conduct and transparency to foster trust in the pharma industry

  • Sustainable Development Goal 3 (Ensure healthy lives and promote well-being for all at all ages)
  • Overcome the social challenges raised by Japan’s aging population
  • Ethical soundness, code of behavior, and transparency
  • Boost public literacy in health and medicine
  • Social significance of pharmaceuticals and the pharma industry
  • Encourage the public and younger people to enter the pharma industry
  • Climate change
  • Environmental issues
Patient and the public perspective

JPMA's Vision

Member Companies

JPMA has 68 research-and-development-oriented pharmaceutical companies as members (as of October 1, 2026).

List of Member Companies

Special Sites & Related Sites